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Abstract
The nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling appears to play 
a key role in inhibiting neuroinflammation and preventing the activation of a proapop-
totic pathway, thereby promoting neural cell survival. In addition, evidence indicates 
that cGMP/protein kinase G (PKG) pathway is involved in the modulation of glial cell 
activity. Phosphodiesterase 5 (PDE5), which hydrolyzes cGMP in the inactive form, 
5ʹGMP, is present throughout the body and brain and has emerged as a potential thera-
peutic target for diseases related to neuroinflammatory and neurodegenerative pro-
cesses, since their inhibition leads to accumulation of cGMP. The objective of this chapter 
is to review current knowledge of NO/cGMP signaling pathways on neuroinflammation 
and the potential therapeutic use of PDE5 inhibitors (PDE5-Is) in neurological diseases. 
The extensive, while recent, literature on the effects of PDE-Is on Alzheimer’s disease 
(AD), multiple sclerosis (MS), Parkinson’s disease (PD), Huntington’s disease (HD), and 
stroke has been reviewed.
Keywords: PDE5 inhibitors, neurological diseases, glial cells, cGMP signaling, 
neuroinflammation, neurodegeneration
1. Introduction
A growing number of studies have explored the interaction between the nervous and immune 
systems during the development of neurological disorders. The central nervous system (CNS) 
is an environment considered “immunologically privileged,” as many antibodies and periph-
eral immune cells are blocked by the blood-brain barrier (BBB), a highly specialized brain 
endothelial structure composed of pericytes, astrocytes, and microglia, which does not allow 
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the passage of peripheral immune cells and whose resident cells express little major histo-
compatibility complexes I and II (MHC-I and MHC-II) receptors, as well as low levels of pro-
inflammatory cytokines. However, in damage situation, glial cells show increased expression 
of MHC, Toll-like receptors (TLRs), and proinflammatory cytokines (such as TNF-α, IFN-γ, 
IL-1β, and IL-6). Innate immune response mediated by glial cells seems to be crucial for the 
progression of many neurodegenerative diseases including Alzheimer’s disease (AD), mul-
tiple sclerosis (MS), and Parkinson’s disease (PD). Thus, neuroimmunology emerged as an 
intersection between the nervous system disease mechanism and therapeutic targets.
The nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling appears to play an 
essential role in inhibiting neuroinflammation and in preventing the activation of a proapoptotic 
pathway, thus promoting neural cell survival. Phosphodiesterase type 5 inhibitors (PDE5-Is) 
have recently emerged as a potential therapeutic strategy to modulate neuroinflammation. 
Mechanistically, PDE5-Is exert anti-inflammatory and neuroprotection effects by inhibiting 
PDE5 with subsequent accumulation of cGMP and activation of protein kinase G (PKG). The 
objective of this chapter is to review present knowledge of the NO/cGMP signaling pathways 
on neuroinflammation and the potential therapeutic use of PDE5-Is on neurodiseases.
2. The role of NO/cGMP signaling on inflammation
Cyclic nucleotides, cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophos-
phate (cGMP) exert many physiological roles such as the regulation of ion channels, relaxation 
of smooth muscle, immunomodulation, inflammation, cell proliferation and apoptosis, insulin 
secretion and glycogen synthesis/glycogenolysis, lipogenesis and lipolysis steroidogenesis, 
phototransduction as well as neuronal survival, and consolidation of memory. Both cAMP and 
cGMP can alter cell function by activating or inactivating proteins by phosphorylation. The 
most important regulation of cyclic nucleotides is achieved in negative feedback by activating 
phosphodiesterases (PDEs), which hydrolyses the cAMP and cGMP in their inactive forms, 
5ʹAMP and 5ʹGMP, respectively [1–3].
Synthesis of intracellular cAMP from adenosine 5ʹ-triphosphate (ATP) by membrane-bound 
adenylyl cyclase (AC) is mainly regulated by G proteins. The response to activation of 
G-protein-coupled receptors (GPCRs) transduces a variety of extracellular signals and then 
to intracellular signals, regulating cellular responses [4]. The key transducer of cAMP signals 
is the cAMP-dependent protein kinase A (PKA). Upon binding of cAMP to the regulatory 
PKA subunits, it dissociates into two free regulatory and two catalytic subunits. The liberated 
active catalytic PKA subunits can phosphorylate serine and threonine residues on substrate 
proteins, including the transcription factor cAMP-response element-binding protein (CREB). 
There are some alternative PKA-independent cAMP actions, such as the immunomodulatory 
effects in monocytes and macrophages of guanine exchange proteins directly activated by 
cAMP (EPAC-1 and EPAC-2) [5, 6].
Synthesis of cGMP is mediated by membrane-bound/particulate (pGC) and cytosolic/soluble 
(sGC) guanylate cyclases, which convert guanosine 5ʹ-triphosphate (GTP) into cGMP. sGC is 
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activated by NO released by the endothelium and neurons, whereas pGCs (GC-A, GC-B, and 
GC-C) are activated by binding of specific peptides. GC-A present in the kidney is responsible 
for controlling natriuresis and blood pressure through stimulation by atrial natriuretic peptide 
(ANP) and brain-type natriuretic peptide (BNP), which are released from the heart. In the 
small intestine, GC-C stimulates secretion of fluids through activation by intestinal peptide, 
guanylin [7]. The physiological effects of cGMP activities are determined by three types of 
intracellular targets: cGMP-dependent kinases (PKG), cyclic nucleotide-gated channels, and 
cGMP-binding PDEs [8]. In some cell types, it modulates the concentration of cAMP by acti-
vating PDE2 or inhibiting PDE3 activity [9, 10].
cGMP plays an important role as a mediator of the action of NO. NO is highly reactive and 
unstable free radical, which regulates a variety of cellular functions by diffusion from its origi-
nating cell to surrounding cells [11]. The NO can be synthesized by three NO synthase (NOS) 
isoforms, namely, neuronal synthase (nNOS or NOS-I), inducible form (iNOS or NOS-II), 
and the endothelial form (eNOS or NOS-III). The constitutive isoforms, eNOS and nNOS, are 
anchored on the internal surface of the cell membranes, and their activities by the endothe-
lial cells and neurons are responsible for maintenance of physiological homeostasis such as 
blood pressure and blood flow, platelet aggregation, leukocyte adhesion to the endothelium, 
and neuronal signaling. eNOS and nNOS produce NO under physiological conditions and 
are primarily regulated by intracellular Ca2+/calmodulin levels. The inducible isoform iNOS is 
Ca2+ independent and represents a newly synthesized enzyme, which is expressed in response 
to specific stimuli, such as endotoxin and cytokines. iNOS is present in macrophages, hepa-
tocytes, smooth muscle, endothelium, and glial cells and produces NO after immunological 
stimulation [i.e., IFN-γ, TNF-α, lipopolysaccharide (LPS)]. Whereas eNOS and nNOS produce 
NO for a short period of time (seconds or minutes), iNOS produces NO for long period of 
time (hours to days) and typically synthesizes 100–1000 times more than constitutive NOS 
[12, 13]. At high levels, NO produced by iNOS exerts cytotoxic and pro-inflammatory effects; 
however, the low nanomolar concentrations of NO produced by the eNOS isoform exhibit anti-
inflammatory effects via the cGMP signaling and perhaps other mechanisms [14, 15]. The NO 
pathway can inhibit vascular nuclear factor-kappaB (NF-κB), a key transcriptional mediator of 
inflammation, by increasing the expression of cytoplasmic and nuclear levels of its inhibitor, 
the IκB-α [16], or by directly inhibiting the NF-κB binding [17]. Moreover, eNOS regulates 
NF-κB expression in a negative feedback mechanism, limiting local inflammation [18].
Studies developed on knockout mice for NOS isoforms indicate that NO derived from eNOS 
and nNOS is critical in the regulation of leukocyte-endothelial cell interactions in postcapil-
lary venules [19, 20]. NO produced by the vascular endothelium exerts a cytoprotective and 
antithrombotic role by preventing the activation and adherence of leukocytes and platelets. 
The anti-inflammatory effects of NO are mediated predominantly via the activation of sGC 
and subsequent formation of cGMP. The production of cGMP causes specific downregulation 
of the expression of P-selectin on endothelial cells and platelets to prevent leukocyte rolling, 
adhesion, and migration [21].
The NF-κB is the generic name of a family of transcription factors that functions as dimers and 
regulates gene expression of a plethora of inflammatory and immune mediators, including 
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cyclooxygenase-2 (COX-2) and iNOS, both considered important mediators in the recruitment 
of inflammatory cells [22–24]. The NF-κB proteins are sequestered in the cytoplasm through 
physical interaction with IκB family proteins. Proinflammatory cytokines (IL-1, TNF-α), B- 
and T-cell activators, pathogen-associated molecular patterns (PAMPs), and oxidative stress 
activate IκB kinase (IKK), a cytoplasmic kinase complex, that phosphorylates the IκB mol-
ecules, leading to their subsequent degradation through the ubiquitin–proteasome pathway. 
NF-κB dimers then translocate to the nucleus where they can bind to κB consensus sequences 
and activates the transcription of various genes [4]
Cyclic AMP/PKA modulates the NF-κB function through several events; some of them 
include CREB-mediated transcription of the IκB gene, thus elevating the expression of 
resynthesized IκB, inhibiting IκB degradation via blocking of IKK activity, and enhancing 
IκB levels by interfering with Iκ ubiquitination and/or subsequent proteasomal degradation 
[25–28].
Intracellular levels of cGMP also exert a role in modulating inflammatory response. Initially, 
some studies demonstrated that inhibition of endogenous NO production markedly increased 
monocyte chemoattractant protein-1 (MCP-1) mRNA levels in endothelial cells, whereas 
exogenous addition of NO dose dependently decreased MCP-1 mRNA expression and secre-
tion [29]. This NO modulating effect of MCP-1 expression occurs via suppression of NF-κB 
by reducing the degradation of IκB [30, 31]. In sequence, a detailed study described the NO/
cGMP role in regulating the inflammatory response. According to Aiwaza and cols [9], NO 
and C-type natriuretic peptide (CNP) inhibit NF-κB activity via cGMP-dependent activation 
of PKA, but not of PKG. In summary, the cGMP elevated levels by NO donor or natriuretic 
peptide inhibited PDE3 activity, which lead to the increase of cAMP and activation of PKA. 
PKA inhibited NF-κB transcription activity and, subsequently, the downstream MCP-1 and 
vascular cell adhesion molecule-1 (VCAM-1) gene expressions.
Moreover, there are other mechanisms by which NO/cGMP regulates the NF-κB activation 
and MCP-1 expression, such as activation of mitogen-activated protein kinase (MAPK) phos-
phatase-1 (MKP-1) and, ultimately, inhibition of p38 MAPK, suggesting a counter-regulatory 
action of p38 MAPK and NF-κB [32].
In addition to anti-inflammatory effects, NO can have both pro- and anti-tumorigenic activi-
ties depending on NOS uncoupling that can occur under some conditions, such as low [Arg] 
or elevated levels of endogenous NOS inhibitors. Uncoupled NOS produces oxidants like 
peroxynitrite and O2, which initiates different downstream signaling that for tumor cells are pro-proliferative and antiapoptotic, e.g., NF-κB. However, when the primary product of 
NOS is NO, downstream signaling is dominated by anti-tumorigenic NO-dependent path-
ways (sGC/cGMP/PKG) [33]. The NO/cGMP/PKG pathway appears to play an essential role 
in promoting apoptosis, thus inhibiting tumor growth. Activating cGMP/PKG pathway by 
PDE5 inhibitors selectively inhibits colon tumor growth, as well as the knockdown of PDE5 
in colon cancer cell (HT-29) by siRNA efficiently promotes apoptosis and delayed prolifera-
tion [34, 35]. Recently, it was also demonstrated that increased intracellular levels of cGMP 
induced by the inhibition of PDE5 significantly inhibit colonic tumorigenesis dependent on 
inflammation [36].
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However, NO/cGMP/PKG actions appear to be highly cell type and context dependent. In 
some neural cells, the NO/cGMP/PKG pathway has an essential role as an antiapoptotic/
prosurvival factor [37]. This neuroprotective mechanism may be especially important during 
brain ischemia, inflammation, or trauma. In retinal neuroglial progenitor cells, NO/cGMP/
PKG antiapoptotic cascade is activated through Akt-induced CREB1 activation [38, 39]. CREB 
is a transcription factor involved with neurotransmitters, growth factors, and other signaling 
molecules with essential functions for memory and neuronal survival [40, 41]. In cerebellar 
granule neurons, there is evidence that NO plays an active role in sustaining the neuronal 
survival through NO/cGMP/PKG [42].
cGMP/PKG1 is also considered as a key effector in cardioprotection induced by PDE5 inhibi-
tors against ischemic injury in the infarcted heart and cardiomyocytes. The potential mecha-
nisms include its antiapoptotic effect as is evident by increased phosphorylation of Akt (pAkt) 
and glycogen synthase kinase 3β (pGSK3β), Bcl-2 expression, and prevention of caspase-3/
caspase-7 activation [43–45]. Other studies provided the evidence that PDE5 inhibition pro-
longed survival of transplanted of bone marrow-derived mesenchymal stem cells in ischemic 
heart via cGMP/PKG signaling, contributing to regeneration of the ischemic heart [46].
3. The role of glial cells on neuroinflammation: the modulation by  
NO/cGMP
Several lines of evidence strongly suggest that neuroinflammation is a crucial process involved 
in the progression of neuronal degeneration, a common feature observed in several neurode-
generative disorders. Therefore, the involvement of the local innate immune response can be 
a very complex process, contributing to perpetuate the damage to the CNS [47].
In the inflammatory process, there is an increase in blood flow and vascular permeability, 
venular dilatation, and recruitment of cells to the inflammatory site. Reactive oxygen species 
(ROS) play an important role in the inflammatory process, including endothelial cell damage 
and increased microvascular permeability, chemotactic factor production, neutrophil recruit-
ment, oxidation, and lipid peroxidation [48]. These inflammatory mediators play a regulatory 
role in the growth, differentiation, and activation of immune cells [49]. Glial cells (microglia, 
astrocytes, and oligodendrocytes) define brain homeostasis and are responsible for defense 
against neural tissue injury [50, 51].
3.1. Astrocytes
Astrocytes constitute a very heterogeneous population of cells, which regulate pH, extracel-
lular levels of ions, neurotransmitters, and energy metabolism. They are involved in the for-
mation and functioning of BBB [52] and also actively participate in neurotransmission [53]. 
In situations of CNS damage, the typical response is some degree of reactive gliosis [54], 
an astrocytic response involving positive gene regulation of cytoskeletal proteins (e.g., glial 
fibrillary acid protein, GFAP), hypertrophy, hyperplasia, and rearrangement of astrocytes, 
which may form glial scars [50].
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In addition, astrocytes play an important role in central immunity. The innate immune 
response is precisely adjusted by identifying the type of threat that is present. Molecular 
structures associated with the threat are recognized by pattern recognition receptors (PRRs). 
PRRs recognize PAMPs, expressed by bacteria, fungi, and viruses, or damage-associated 
molecular patterns (DAMPs), expressed by cells and tissues under stress or injury. One of 
the major classes of PRRs in mammals is TLRs. The response is rapid both to the presence of 
pathogens and to other types of damage to the tissue, activating the immune system, which 
releases cytokines and chemokines, and modulating the BBB [50].
Astrocytes express TLRs [55]. The brain and spinal cord of multiple sclerosis patients showed 
increased TLR3 and TLR4 in astrocytes in regions of inflammation [56]. Most TLRs, after 
detecting their respective ligands, initiate a signal that is mediated by the myeloid differen-
tiation gene 88 (Myd88) and result in the activation of nuclear transcription factor NF-κB. 
Translocation of NF-κB to the nucleus culminates in the secretion of proinflammatory mol-
ecules (IL-1β, IL-6, TNF-α, and IL-12). Activated astrocytes may also produce chemokines that 
recruit microglial cells, lymphocytes, and dendritic cells to the site of injury [57].
In the astrocytic response, in addition to increased TLR4 levels, leading to the expression 
of a variety of chemokines and cytokines [55, 58], other important processes occur, such as 
alteration of intracellular calcium signaling. Under conditions that lead to neuroinflammation 
in the CNS, as in exposure to LPS, Ca2+ signaling in the astrocyte network is over activated, 
triggering astrocyte activation. The inhibition of the communicating junctions (gap junctions), 
with changes in intercellular Ca2+ waves and Na+/K+-ATPase activity, results in disorganiza-
tion of the actin filaments (stress fibers) [58, 59], and these effects are hallmarks of astrocyte 
reaction on neuroinflammation.
Evidence indicates that the cGMP/PKG pathway is involved in the regulation of astrocytic 
activity [60]. The NO, through the cGMP/PKG, decreased intracellular Ca2+ in astrocytes, 
reducing intercellular Ca2+ waves [61]. In addition, cGMP inhibited IFN-γ-induced MHC-II 
expression, as well as the expression of LPS-induced matrix metalloproteinase-9 (MMP-9) 
and TNF-α in cultured astrocytes [13, 60, 62]. According to these studies, MMP-9 expression 
is dependent on extracellular signal-regulated kinase (ERK) activation via NF-κB. This data 
supports the hypothesis that the NO/cGMP/PKG pathway plays a role in astrocytic cells that 
contributes to the resolution of neuroinflammation.
3.2. Microglia
Microglia constitute the cells that are part of the innate immune system and are therefore 
considered as the pathological sensors of the CNS damage. The phenotypic changes of the 
microglia after activation are functionally identical to those observed in macrophages [63, 64]. 
The physiological functions of microglia are important for the maintenance of homeostasis. 
In addition, they have been shown to be responsible for the secretion of neurotrophic factors, 
such as the brain-derived neurotrophic factor (BDNF) [65] and for removing aggregates of 
proteins [66]. However, when exposed to infections, lesions, or dysfunction of the nervous 
system, microglial cells become activated. In the absence of pathology, the microglia “at rest” 
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are small cells with long and thin processes (“branched phenotype”). When activated, the 
microglia loses the long extensions typical of the inactive microglia and exhibits ameboid 
extensions (“ameboid phenotype”) [67]. Protein Iba-1, expressed on the microglia surface, 
is used as a marker of its activated state [68]. This physiological transformation is associated 
with changes in the expression of surface receptors and the release of cytokines, which may 
contribute to the damage of synaptic plasticity and the neurodegenerative disease aggrava-
tion [69].
Activated microglial cells become a source of TNF-α, IL-1β, IL-1α, superoxide, NO, chemo-
kines, and glutamate, which may promote neuronal death. TNF-α, secreted both by microglia 
and astrocytes, can directly promote neuronal death by binding to its corresponding recep-
tors (TNFRs). Evidence indicates that TNF-α induces apoptosis of mature oligodendrocytes in 
inflammatory demyelinating diseases such as multiple sclerosis [61, 70] and plays a key role 
in neurodegeneration process observed in Parkinson’s and Alzheimer’s diseases [57].
An in vitro study using N9 microglial cells demonstrated that the treatment with the PDE5 
inhibitor, sildenafil, suppressed NO, IL-1β, and TNF-α production induced by LPS, due to 
suppression of the MAPKs/NF-κB pathways through the inhibition of NADPH oxidase, 
mediated ROS generation [71]. These results indicate that cGMP accumulation as a result of 
PDE5 inhibition might participate in the inhibition of microglial activation.
3.3. Oligodendrocytes
Oligodendrocytes are myelinizing CNS cells that arise from oligodendrocyte progenitor cells 
(OPCs). OPCs differentiate in mature or myelinizing oligodendrocyte, fixing extensions in 
axons to generate the concentric membrane layers to produce myelin. The presence of oli-
godendrocytes is more common in the white matter of neuronal tissue, such as the corpus 
callosum and cerebellum, and less frequent in gray [72]. In both compartments, myelin is 
necessary for the saltatory conduction of action potentials along axons [73].
Oligodendrocyte dysfunction and myelin abnormalities are found in a wide variety of neu-
rological diseases and may be involved in the pathophysiology of various diseases, including 
genetic leukodystrophies [74], schizophrenia and bipolar disorder [75, 76], brain injury [77], 
and endocrine and metabolic abnormalities [78, 79] and neurodegenerative conditions such as 
strokes [80, 81], Parkinson’s disease [82], Alzheimer’s disease [83–85], multiple sclerosis [86], 
and diabetic encephalopathy [87].
In an attempt to repair myelin damage, increased differentiation of OPCs into mature oligo-
dendrocytes promotes remyelination [88]. In later stages of injury, however, OPCs also enter 
into apoptosis. Recent studies have shown that treatment with sildenafil increases the levels 
of the protein expressed by oligodendrocytes, myelin basic protein (MBP), and also restores 
myelin sheath morphology, indicating remyelination. In addition, sildenafil induces the dif-
ferentiation of OPCs into mature oligodendrocytes, as demonstrated by the increase of gluta-
thione S-transferase pi (GST-pi, a marker of mature oligodendrocytes), indicating that cGMP 
signaling can modulate OPC survival and myelin production [89].
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Oligodendrocytes are not inert immune cells, but secrete a wide variety of inflammatory 
mediators, such as the proinflammatory cytokines IL-1-β and IL-6 and CCL-2 and IL-8 che-
mokines involved in the recruitment of immune cells during inflammation [90]. In experi-
mental multiple sclerosis models, oligodendrocytes in apoptosis also express increased levels 
of COX-2 at the demyelination beginning, which seem to make these cells more susceptible to 
death by glutamate-mediated excitotoxicity [91].
4. Therapeutic applications of phosphodiesterase 5 inhibitors in  
central neurological diseases
Faced with rising costs for the development of new drugs, researchers are looking for ways 
to repurpose older ones. Taking medications that have been developed for one disorder—and 
even some that fail in initial trials—and “repositioning” them to tackle another are a growing 
strategy for researchers in industry and academia [92].
The administration of selective PDE5-Is increases the levels of cGMP [93, 94], with effects on 
multiple organs and systems. The PDE5-I, sildenafil, is a medication for angina pectoris devel-
oped in 1989 [92]. For many years, sildenafil (Viagra®, Pfizer) has been the most representative 
molecule of the class of drugs to treat erectile dysfunction (ED) [95]. Under the trade name 
Revatio® (Pfizer), it was also approved for pulmonary artery hypertension therapy in June 
2005 [96] and, more recently, for the Raynaud’s phenomenon [97]. Therefore, sildenafil is a 
classic success story of repositioning.
PDE5 is present throughout the body and brain [95, 98] and has emerged as a potential ther-
apeutic target for diseases related to neuroinflammatory and neurodegenerative processes 
because of its reported relation with them (for review, see [99]). To date, only four PDE5-Is 
have been approved by the US Food and Drug Administration (FDA) and by the European 
Medicines Agency: sildenafil, vardenafil, tadalafil, and avanafil. Sildenafil is reported to 
clearly cross the BBB [100], whereas evidence for vardenafil is indirect [101] and, while it was 
first considered that tadalafil does not cross it [102], later was demonstrated that this drug is 
able to cross the barrier [103]. Several studies indicate that sildenafil and other PDE5-Is may 
offer novel strategies for the treatment of neurological pathologies [12, 102, 104]. The benefi-
cial effects of PDE5-Is were initially attributed to its mechanism in smooth muscle (regulating 
blood flow) and improving synaptic plasticity and neurogenesis. However, recent studies 
point to an important effect of these drugs on neuroinflammation, which may be, at least in 
part, responsible for their protective effects on central neurological diseases.
Thus, five major mechanisms of PDE5-Is have been described in neurological disease mod-
els: (1) by modulating the CREB pathway, inducing the formation of new synaptic connec-
tions and neurogenesis, improving cognition and memory; (2) through the modulation of 
Akt/GSK3β and calpain/p25/CDK5 pathways, decreasing aggregate formation of proteins; 
(3) through apoptosis inhibition; (4) by inducting angiogenesis and improving blood flow; 
and (5) through the modulation of neuroinflammation. Targeting multiple elements in the 
network underlying complex diseases, such as neurological diseases, may produce benefits 
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beyond those of representative monotherapies [105, 106]. Repositioning PDE5-Is as therapeu-
tic approaches that can be used in combination with other drugs can therefore be useful. This 
section aims to name and classify representative preclinical and clinical studies of PDE5-Is 
in central neurological diseases (Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, 
Huntington’s disease (HD), and stroke) and to describe the main known mechanisms, with 
emphasis on neuroinflammation (following a search of the Medline®/PubMed® database, dur-
ing the period between 2000 and 2016).
4.1. Alzheimer’s disease
Alzheimer’s disease (AD) has become the fourth leading lethal disease among the elderly after 
cancer, heart disease, and stroke. It is an age-related neurodegenerative disease character-
ized by the presence of senile plaques (consisting of β-amyloid filaments, Aβ), neurofibrillary 
tangles (composed of hyperphosphorylated tau deposits), and neuronal degeneration accom-
panied by significant loss of synapses [107, 108] (Figure 1A). While early studies focused on 
assessing the beneficial effects of PDE5-Is on AD through the formation of synapses, neuro-
genesis, and protein aggregation pathways, more recent studies have shown that the role of 
these drugs in neuroinflammation may be an important mechanism in AD.
4.1.1. PDE5-Is’ beneficial effects in AD through CREB/BDNF/Arc pathway, Akt/GSK3b pathway, 
and calpain/p25/CDK5 pathway modulation
cGMP/PKG pathway contributes to phosphorylation of the transcription factor CREB; 
Prickaerts et al. [109] suggested that the cGMP/PKG/CREB pathway induces the synthesis of 
proteins essential for memory consolidation, probably through the formation of new synaptic 
connections [110]. Therefore, the chronic administration of PDE5-Is may lead to gene tran-
scription through CREB activation, by raising cGMP levels (Figure 2A).
Puzzo et al., in 2009 [102], and Cuadrado-Tejedor et al., in 2011 [111], showed that sildenafil 
has beneficial effects on AD models, modulating the CREB pathway. Puzzo et al. [102] dem-
onstrated that sildenafil (3 mg/kg, i.p., for 3 weeks) may be beneficial against cognitive loss 
in the APP/PS1 mouse model of amyloid deposition, producing an immediate and lasting 
improvement of synaptic function, CREB phosphorylation, and memory. This effect was asso-
ciated with a reduction in Aβ levels. Cuadrado-Tejedor et al. [111] showed that sildenafil 
(15 mg/kg, i.p., for 5 days) restored cognitive deficits in aged rat model of AD (Tg2576-AD 
transgenic mice); however, whereas pCREB was not significantly induced in mice treated 
with sildenafil, the BDNF and Arc (CREB downstream target molecules) increased, confirm-
ing that the drug acts through this pathway (CREB/BDNF/Arc), inducing synaptic formation 
and improving memory.
Cuadrado-Tejedor and coworkers [111] showed, however, that sildenafil did not affect 
Aβ-burden while decreased tau phosphorylation. The formation and aggregation of Aβ and 
tau involve some pathways, which can be plausible therapeutic target for the treatment of 
AD. GSK3β, which is inhibited by Akt, and cyclin-dependent kinase 5 (CDK5), which is acti-
vated by p25, are the most relevant kinases involved in the pathogenic mechanisms of AD 
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by phosphorylation at multiple sites of the microtubule-binding protein, tau [112, 113]. The 
activities of GSK3β and CDK5 were reduced by sildenafil, whereas the drug increased Akt 
and decreased p25. The decrease in kinase activity of GSK3β and CDK5 due to sildenafil 
may lead to a reduction in tau phosphorylation, possibly contributing to the reestablishment 
of cognitive function (Figure 2B). Then, according to Cuadrado-Tejedor et al. [111], silde-
nafil reversed the marked memory deficits of elderly Tg2576 animals by regulating the Akt/
GSK3β/pTau and p25/CDK5/pTau pathways, not resulting from any decrease in the Aβ-load. 
However, the contrasts between Cuadrado-Tejedor et al. [111] and Puzzo et al. [102] may be 
Figure 1. Hallmark pathologies of (A) Alzheimer’s disease (AD), (B) multiple sclerosis (MS), (C) Parkinson’s disease 
(PD), and (D) Huntington’s disease (HD). (A) In AD, neurons contain intracellular neurofibrillary tangles composed 
of hyperphosphorylated tau protein and extracellular plaques of amyloid β (Aβ). The inflammatory reaction, with 
activation of microglia and astrocytes and the subsequent release of inflammatory cytokines and reactive oxygen species 
(ROS), plays a significant role in the pathological processing of AD. (B) MS is a chronic autoimmune/inflammatory 
disorder characterized by demyelination of axons, with associated acute and chronic inflammatory events involving the 
recruitment/activation of microglia/macrophages, astrocytes and B and T cells and release of proinflammatory cytokines, 
ROS, and autoantibodies. (C) In PD, neurons contain α-synuclein aggregates, forming Lewy bodies. Neuronal loss leads 
to lower production of dopamine. There is a persistent inflammatory response, T-cell infiltration, and glial cell activation 
in patients with PD and animal models, which play a crucial role in the degeneration of dopaminergic neurons. (D) In 
HD, mutant huntingtin protein (mhtt) containing an extended polyglutamine repeat, caused by at least 36 CAG repeats 
in the huntingtin gene, leads to intraneuronal aggregates. In all four diseases, the pathological events ultimately result 
in neuronal death. Over time, this either causes or contributes to neuroinflammation.
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due to differences between dose, duration of treatment, and animal models. In addition, both 
Akt/GSK3β and p25/CDK5 signaling are also involved in the regulation of Aβ [114], and it is 
possible that if the treatment was longer, this effect would be detected.
Following the same line of investigation, Orejana et al. [114] treated senescence-accelerated 
mouse-prone 8 (SAMP8, used as a model of aging, which displays many established path-
ological features of AD) with sildenafil (7.5 mg/kg, i.p., for 4 weeks) and showed that the 
mechanism of protection is through Aβ decrease, by pAkt/GSK3β /cathepsin B pathway and 
calpain/p25/CDK5/BACE1 pathway inhibition. pAkt inhibits GSK3β, which is an important 
activator of cathepsin B [115]. Calpain is an enzyme that cleavages p35 in p25, and p25/CDK5 
regulates BACE1 (protein cleaving enzyme 1) expression levels. BACE1 and cathepsin B (both 
β-secretases) cleavage amyloid precursor protein (APP), contributing to the formation of Aβ. 
Sildenafil decreased the activity of calpain, p25, and CDK5 and markedly increased Akt phos-
phorylation and decreased GSK3β activity. Consequently, sildenafil decreased the expression 
Figure 2. PDE5-I mechanisms in the CREB pathway and protein aggregation. (A) The PDE5 inhibitors (PDE5-Is) 
modulate the CREB pathway, increasing the expression of CREB and the downstream targets, BDNF, and Arc. The 
result is the induction of new synaptic connections and neurogenesis, leading to the restoration of pathological cognitive 
signs of neurological diseases, such as Alzheimer’s disease and Huntington’s disease. (B) PDE5-Is also modulate 
pathways involved in the protein aggregation. Calpain is an enzyme that cleavage p35 in its more stable isoform, p25. 
The formation of the p25/CDK5 complex is associated with tau hyperphosphorylation. In addition, p25/CDK5, via the 
downstream target BACE1, also leads to cleavage of amyloid precursor protein (APP), contributing to the formation of 
Aβ plaques. PDE5-Is induce a decrease in the activity of calpain, p25, and CDK5, with consequent decrease in protein 
aggregation. GSK3β is a kinase involved in the hyperphosphorylation of Tau. In addition, through the downstream 
target, cathepsin B, GSK3β leads to the formation of Aβ plaques. pAkt is a GSK3β inhibitor, modulating the pathway. 
PDE-Is increase Akt phosphorylation and decrease GSK3β activity and cathepsin B expression, which can contribute 
to control the protein aggregation.  Inhibition  ; activation;  increased expression/activity;  decreased 
expression/activity.
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of BACE1 and cathepsin B, leading to a reduction in APP and Aβ levels (Figure 2B). These 
findings demonstrate that sildenafil modulates calpain/p25/CDK5/BACE1 and pAkt/GSK3β/
cathepsin B pathways, and these mechanisms are probably responsible for beneficial effects 
of this class of drugs in AD models.
4.1.2. PDE5-Is beneficial effects in AD through the control of neuroinflammation
Although the first PDE5-I studies in AD models have been focused on synapse formation, 
neurogenesis, and memory improvement, investigating primarily CREB, tau phosphoryla-
tion, and Aβ formation pathways, more recent studies also point to an important anti-inflam-
matory mechanism of this class of drugs in AD. The work by Orejana et al. [114] was perhaps 
one of the first studies to suggest and demonstrate that sildenafil modulates inflammatory 
cells in AD model. They showed that sildenafil decreased the GFAP, a marker of astrogliosis. 
However, Orejana et al. [114] could not differentiate whether the reduction in GFAP levels 
resulted from less accumulation of Aβ or if it was a direct modulation of inflammatory events 
by sildenafil. A recent study using sildenafil in cultured astrocytes confirmed that sildenafil 
has a direct mechanism on neuroinflammation [116].
Until 2013, it was unknown whether PDE5-Is reversed Aβ-induced neuroinflammation in 
APP/PS1 transgenic mice. Zhang et al. [117] showed that APP/PS1 mice presented impaired 
cognitive ability, neuroinflammatory response in the hippocampus, and downregulated 
cGMP; sildenafil reversed memory deficits and cGMP/PKG/pCREB signaling dysfunction 
and reduced Aβ levels in this model. In addition, sildenafil decreased the proinflammatory 
cytokines IL-1β, IL-6, and TNF-α. The inhibition of hippocampal PKG immediately prior to 
the injection of sildenafil significantly blocked these effects, further indicating the participa-
tion of PKG in the anti-inflammatory effects produced by sildenafil (Figure 3A, B).
An ongoing neuroinflammatory process has been considered a marker of AD [117]. The depo-
sition of Aβ peptides and the activation of glial cells surrounding senile plaques in brain 
areas involved in cognitive functions are assumed to participate in the onset of a pathological 
cascade resulting in synaptic dysfunction, synaptic loss, and neuronal death [118, 119]. The 
inflammatory reaction, with activation of microglia and astroglia, and the subsequent release 
of inflammatory cytokines (IL-1β, TNF-α, and COX-2 and so on) play a significant role in the 
pathological processing of AD [108] (Figure 1A). Proinflammatory cytokines, such as TNF-α 
and IL-1β, may contribute to brain dysfunction and neurodegeneration, impair synaptic plas-
ticity, and induce memory impairment, while the anti-inflammatory cytokine IL-4 has the 
opposite effect [120, 121]. NF-κB is well known as a key regulator that induces the expression 
of many proinflammatory cytokines and inducible effector enzymes linked to the inflamma-
tory process. The degradation of IκB-α (NF-κB inhibitory protein) and NF-κB phosphoryla-
tion were enhanced after the Aβ injection [108].
Additionally to classical PDE5-Is, other drugs have been demonstrated to act on AD by inhib-
iting PDE5 and modulating neuroinflammation. It has recently been showed by Li et al. [108] 
that sodium hydrosulfide (NaHS), a hydrogen sulfide donor, decreased PDE5 levels, attenu-
ated neuronal death, and suppressed apoptosis by inhibiting the activation of pro-caspase-3 in 
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the hippocampus of Sprague-Dawley rats (injected with aggregated Aβ25-35). NaHS upregu-
lated the expression of peroxisome proliferator-activated receptors (PPAR-α and PPAR-γ), 
which antagonize the effects of NF-κB [122]. Moreover, the Aβ25-35-injected rats exhibited a 
decrease in IκB-α degradation and an increase in NF-κB p65 phosphorylation levels, whereas 
Figure 3. PDE5 inhibitors modulate neuroinflammation. (A) AMPK exerts its anti-inflammatory activity through 
multiple signaling pathways. The phospho-AMPK (pAMPK) suppresses NF-κB, by increasing its inhibitory protein, 
IKβ-α. Consequently, the production of cytokines is decreased. In addition, AMPK phosphorylates and activates eNOS, 
inducing NO production; eNOS increases AMPK, in a positive feedback, and NO can act as an endogenous activator 
of AMPK, suggesting a reciprocal relationship between AMPK and eNOS. eNOS also inhibits NF-κB, decreasing the 
inflammatory response. PDE5-Is increase pAMPK and eNOS expression, increase IKβ-α, and decrease NF-κB. NO 
activates sGC, inducing cGMP production, which can amplify the effect of PDE5-Is. (B) Some possible mechanisms 
of PDE5-Is in the control of neuroinflammation have been demonstrated while not fully understood. PDE5-Is increase 
levels of the chemokine MCP-1 and its receptor, CCR-2, which are typically overregulated in multiple sclerosis models. 
It is possible that this effect is indirect, through NO, since this gas was shown to increase MCP-1/CCR-2, but it has not 
been confirmed so far. In addition, PDE5-Is were shown to increase the three isoforms of nitric oxide synthase (nNOS, 
iNOS, and eNOS), along with increased levels of NO. However, the mechanism of NOS participation on the effects 
of PDE5-Is is unclear. ICAM-1 and VCAM-1 were decreased by PDE5-Is, which may be important for the control of 
leukocyte infiltration. It is possible that complex cross signaling is occurring, but although it has been demonstrated 
in inflammatory models, it has not been confirmed in preclinical studies with PDE5-Is in neurological diseases. For 
example, elevated levels of cGMP by NO may inhibit PDE3 activity, which leads to increased cAMP levels and PKA 
activation. PKA inhibits NF-κB transcription activity and, subsequently, the expression of downstream MCP-1 and 
VCAM-1.  Inhibition;  activation;  increased expression/activity;  decreased expression/activity.
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these effects were attenuated by NaHS. NaHS can therefore act as an anti-inflammatory medi-
ator by inhibition of PDE5.
A novel PDE5 inhibitor, Yonkenafil (yonk) (2, 6, or 18 mg/kg i.p.), given daily for 3 months, 
has been shown to have beneficial effects in APP/PS1 mice through anti-inflammatory mecha-
nisms. Yonk reduced the area of Aβ plaques, increased neurogenesis, and inhibited over-
activation of microglia and astrocytes [119]. A recent study by Yin et al. [123] has shown that 
Icariside II (ICSII), another new PDE5 inhibitor, derived from the Chinese herb Epimedium 
brevicornum, has protective effects on the AD model induced by intracerebroventricular strep-
tozotocin (ICV-STZ) in Sprague-Dawley rats. ICSII (10 mg/kg for 21 days) improved cognitive 
deficits, attenuated neuronal death, and decreased Aβ levels by suppressing BACE1 and APP 
expression in the rat hippocampus. In addition, ICSII decreased IL-1β, TNF-α, COX-2, and 
transforming growth factor-β (TGF-β) levels while increasing IκB-α and decreasing NF-κB 
activation.
It was demonstrated by Jin et al. [124] that Icariin (ICA), a flavonoid extracted from Chinese 
herb (Berberidaceae epimedium L.), an effective oral agent, is also a PDE5-I. Chronic treatment 
with ICA (30 and 60 mg/kg, twice a day for 4 months) improved the learning and memory 
of APP/PS1 transgenic mice, and the levels of APP, Aβ, and PDE5 decreased in the hippo-
campus and cortex after ICA treatment. Furthermore, ICA-treated mice showed increased 
expression of three NOS isoforms (nNOS, iNOS, and eNOS), along with increased levels of 
NO and cGMP. These results suggest that NO itself may be involved in the anti-inflammatory 
effect of PDE5-Is. NO is an important molecule in supporting neurite outgrowth and synapse 
remodeling [125, 126]. This study by Jin et al. [124] also showed that the three isoforms of 
NOS and NO levels decreased in the brain of APP/PS1 mice, reinforcing that NO deficiency 
may contribute to AD. Thus, ICA has a neuroprotective mechanism, probably due to stimula-
tion of the NO/cGMP signaling pathway through the inhibition of PDE5 activity and coordi-
nated induction of NOS isoform expression. Corroborating this result, Rapôso et al. [89, 127] 
showed that the absence of iNOS abolished the anti-inflammatory effects of sildenafil in mice 
brains. Treatment with sildenafil for 4 weeks decreased GFAP, COX-2, and the expression of 
various pro-inflammatory cytokines in wild-type C57BL/6 mice, although it did not have anti-
inflammatory effects in iNOS−/− mice. Also, Nunes et al. [128] reported that eNOS is upregu-
lated following chronic administration of sildenafil. These studies point to the relevance of the 
physiologic expression of NOS for the anti-inflammatory mechanism of PDE5-Is (Figure 3B).
Despite the rich (though recent) literature on the effects of the PDE5 inhibitors on animal 
models of AD, clinical studies are lacking. However, PCR analysis of postmortem tissue of 
patients suffering from AD found a considerable increase in PDE5 expression in the temporal 
cortex of the brain compared to healthy controls of the same age [129]. Also, it was observed 
that lower levels of cGMP in the cerebrospinal fluid of patients with AD were associated with 
cognitive decline and amyloid pathology [129]. In addition, a clinical study demonstrated that 
chronic administration of udenafil (Zydena; available in Korea, Russia, and the Philippines) to 
27 patients with ED (100 mg at 3-day intervals for 2 month) has shown to lead to an improve-
ment in cognitive function [130]. This has lead to suggest that sildenafil could improve cogni-
tive function in AD patients.
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Thus, the efficacy and safety of treatment with repeated doses of PDE5-Is have been demon-
strated in several animal models of AD. Since the side effects of PDE5-Is are widely known 
and do not preclude its administration to a senile population, and considering the lack of 
effective treatments for AD, PDE5-Is have been proposed as potential alternatives as cognitive 
enhancers [99, 131].
4.2. Multiple sclerosis
Multiple Sclerosis (MS), the most common neurological disorder in young adults in the 
Western world, is a chronic autoimmune/inflammatory disorder characterized by demyelin-
ation of the nerve cells, which leads to severe psychomotor impairment [132]. CNS demy-
elination is frequently associated with acute and chronic inflammatory events involving the 
recruitment-activation of microglia/macrophages, astrocytes, and leukocytes, with the release 
of pro-inflammatory cytokines, ROS, and NO (Figure 2B) [133, 134]. Neuroinflammatory 
responses appear to begin before any significant loss of neuronal populations in the progres-
sion of MS [135].
It has been demonstrated that NO/cGMP signaling is involved in the regulation of neuro-
inflammation and myelination [89]. The intracellular accumulation of cGMP in different 
models of inflammation reduces the production of proinflammatory cytokines and oxidative 
stress, modulating the inflammatory response [136]. In addition, inhibition of PDEs seems 
to block the inflammatory response of microglia, reducing myelin sheath changes [137, 138]. 
Therefore, neuroinflammation mediated by glial cells (astrocytes and microglia) appears to be 
an important phenomenon that perpetuates neural damage in MS, and since cGMP-mediated 
pathways regulate inflammatory responses in immune and CNS cells, PDE5-Is are potential 
tools for treating MS.
In fact, it has been reported that patients suffering from ED, and in parallel MS, showed an 
improvement in clinical status for both pathologies after treatment with sildenafil [139]. The 
effect of sildenafil on improving the clinical status of patients with MS was initially attrib-
uted to the induction of neurogenesis [140]. However, studies have shown that sildenafil is 
a modulator of inflammation in the central and peripheral nervous systems and protects the 
myelin sheath both in pathological and healthy conditions [89, 116, 127, 128, 140–144]. This 
anti-inflammatory mechanism should better explain the protective effect of PDE5-Is in MS, 
considering the nature of the disease.
In 2011, Pifarré et al. [142] showed that sildenafil (10 mg/kg, s.c., for 18 days) reduced the 
clinical signs of experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, 
developed in female C57BL/6 mice. Sildenafil prevented axonal loss and promoted remyelin-
ation. Furthermore, sildenafil decreased CD3+ leukocyte infiltration and microglial/macro-
phage activation in the spinal cord, while increasing T regulatory cells expressing fork head 
box transcription factor 3 (Foxp3 Tregs) and decreasing ICAM-1 in the infiltrated cells of 
the spinal cord. Autoreactive T cells infiltrating the CNS are the initiator and early effector 
cells in EAE development, but infiltrated macrophages, dendritic cells, and resident microg-
lia constitute the ultimate effector cells that amplify neuroinflammation and tissue injury. 
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ICAM-1, a type-1 membrane-bound glycoprotein expressed in the majority of leukocyte sub-
types, endothelial and CNS glial cells, is involved in leukocyte entry, lymphocyte activation, 
and other immune responses and plays a central role in the development of MS and EAE 
[145, 146]. The decrease of ICAM-1 induced by sildenafil was also reported by Rapôso et al. 
[89]. Pifarré et al. [142] also showed that the presence of astrocytes forming scar-like struc-
tures around infiltrates was enhanced by sildenafil, suggesting a possible mechanism for the 
restriction of the leukocyte dissemination in healthy parenchyma. However, this result does 
not corroborate other studies showing that PDE5-Is decrease GFAP expression and astrocyte 
activation [89, 114, 127, 140].
Continuing the investigation, Pifarré et al. [143] demonstrated that sildenafil treatment 
(10 mg/kg, s.c., for 18 days) preserved axons and myelin and increased the number of remy-
elinating axons in the EAE model; also, sildenafil protected immature and mature myelinat-
ing oligodendrocytes. However, if the protective effect of sildenafil on myelin and axons is 
secondary to its effect, controlling inflammation remains unknown. In addition, sildenafil 
upregulated YM-1, a marker of the macrophage/microglial M2 phenotype that has neuropro-
tective and regenerative properties, while Iba-1, a classical macrophage/microglial activation 
marker, was downregulated. In vitro analyses of spleen cells from sildenafil-treated animals 
showed downregulation of Th1/Th2/Th17 responses, while Tregs were upregulated and pre-
vented accumulation of MOG-specific IgG2b in serum. These results suggest that sildenafil 
has a protective role, modulating central resident and peripheral immune cells.
A sequence of studies has characterized the effects and mechanisms of sildenafil in a cupri-
zone-induced demyelination and neuroinflammation in rodents, which has been widely used 
as a model of MS. Nunes et al. [140] and Rapôso et al. [127] demonstrated that sildenafil 
(25 mg/Kg administrated in the drinking water for 4 weeks) ameliorates cuprizone-induced 
demyelination in C57BL/6 mice. Sildenafil modulated the neuroinflammatory response 
(mediated by glial cells), reducing GFAP and Iba-1, IFN-γ, TNF-α, IL-1β, IL-2, and COX-2 
expressions. However, the anti-inflammatory effect of sildenafil was abolished in the cupri-
zone model induced in iNOS−/− mice [127], showing that iNOS plays an important role in 
the mechanism of PDE5-Is. Sildenafil preserved the myelin and axons’ ultrastructure and 
elevated GST-pi, indicating that sildenafil protects mature oligodendrocytes. However, it is 
not clear if sildenafil induces oligodendrogenesis or if it inhibits cell death/apoptosis or both. 
Myelin protection and oligodendrocyte proliferation have also been demonstrated in isch-
emic models [147, 148], and several studies showed that PDE5-Is inhibit apoptosis in central 
neurological disease models [122, 148, 149].
Contributing to the understanding of the mechanism by which sildenafil acts in the control 
of neuroinflammation in MS model, Nunes et al. [128] investigated the involvement of the 
AMPK/Iκβ-α/NF-κB signaling pathway and the eNOS. AMPK, the regulatory protein of the 
lipid and glucose metabolism, is upregulated in activated astrocytes during reactive gliosis 
[150], whereas AMPK activators downregulate inflammation in vitro and in vivo in various 
animal models [151–153], and the loss of AMPK exacerbates the effects of EAE model [154]. 
The anti-inflammatory activity of AMPK is exerted through multiple signaling pathways, 
including phosphorylation and activation of eNOS and production of NO. NO may act as 
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an endogenous activator of AMPK, suggesting a reciprocal relationship between AMPK and 
eNOS [155]. In addition, recent evidence suggests that the activation of AMPK can suppress 
NF-κB, thus contributing to the regulation of inflammation [71] (Figure 3A). Nunes et al. [128] 
showed that sildenafil treatment (25 mg/Kg administrated in the drinking water for 4 weeks) 
improved the clinical status of the cuprizone-MS mice model. The treatment reduced unphos-
phorylated (inactive) AMPK and increased phospho-AMPK (pAMPK, active). Moreover, silde-
nafil decreased NF-κB p65 expression and increased its inhibitory protein, IKβ-α. However, 
if AMPK induces NF-κB inhibition and which downstream targets may be involved in this 
inhibition require further investigation. The same study showed that sildenafil reduced the 
expression of GFAP, IL-1β, and TNF-α and increased the expression of the anti-inflammatory 
cytokine IL-10. Besides, the level of eNOS was increased by sildenafil, suggesting reciprocity 
between AMPK and eNOS. This study then provides evidence that sildenafil has anti-inflam-
matory effects probably through modulation of AMPK/IKβ-α/NF-κB signaling (Figure 3A). 
However, the involvement of downstream proteins, such as AMPK-SIRT1-NF-κB, and other 
pathways, such as MAPK-NF-κB, should also be further investigated. In addition, Nunes et 
al. [128] showed that eNOS may play a role in the sildenafil mechanism. The possible role of 
NOS in the mechanism of sildenafil corroborates with other studies [89, 124, 127].
The ongoing investigation, in 2016, by Nunes et al. [141] demonstrated that sildenafil increased 
levels of the chemokine MCP-1 and its receptor, CCR-2, in the cuprizone-induced MS model. 
This may be part of the anti-inflammatory mechanism, since CCR-2 is a chemokine closely 
related to the pathology of MS and MS-animal models. In general, during the first weeks 
of cuprizone exposure, it undergoes a typical overregulation of the chemokine, and both 
microglia and astrocytes produce CCR-2 [156]. Also, an increase in CCR-2 may be associated 
with a reduction of macrophage infiltrates after stroke, showing the neuroprotective effects of 
this receptor [157]. Moreover, mediators in the microenvironment define at what time microg-
lia/macrophages can assume an active and phagocytic phenotype [157]. The expression of 
MCP-1/CCR-2 by glial cells may promote this change in microglia phenotype in an attempt 
to repair the injured environment [158]. Sildenafil can, therefore, modulate inflammation by 
playing a role in the regulation of glial cell morphology and activation through MCP-1/CCR-2 
signaling (Figure 3B).
Borán et al. [60] estimated that stimulation of cGMP/PKG pathway acts beneficially in microg-
lia, inducing the phagocytic phenotype (M2) and decreasing expression of inflammatory genes, 
in detriment to the proinflammatory phenotype (M1). The cGMP/PKG pathway stimulated 
the regulation of microglial cell morphology, inducing a dramatic reorganization of the actin 
cytoskeleton compatible with a protective phenotype, which is more effective in the removal of 
dead cells. cGMP-mediated pathways have been implicated in the regulation of the actin cyto-
skeleton and cell morphology in different cell types, including macrophages and astrocytes 
[159, 160]. Borán and García [160] demonstrated that the stimulation of the PKG pathway by 
NO regulates cytoskeleton dynamics and motility in cultured rat astrocytes, and evidence indi-
cates that cGMP is involved in the regulation of astrocyte cytoskeleton through Na+/K+-ATPase 
activity, IP3 receptor (IP3R), and ankyrin B. Ankyrin B, a protein associated with the cytoskel-
eton, interacts with Na+/K+-ATPase and IP3R, connecting the pump to the Ca2+ responses from 
internal cell stores and to the integrity of the cytoskeleton [160] (Figure 4A). This suggests 
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that stress fibers and Ca2+ waves could be changed by sildenafil. The involvement of the cyto-
skeleton in the sildenafil mechanism has been demonstrated by Nunes et al. [116]. Sildenafil 
induced Ca2+ response and a more organized actin fiber pattern in cultured astrocytes, com-
pared to LPS stimulated cells. It is possible that the mechanism behind sildenafil effects in the 
cytoskeleton involves Na+/K+-ATPase, IP3R, and ankyrin B (Figure 4A). In addition, this study 
Figure 4. Mechanisms of PDE5-Is in the cytoskeleton and in the apoptosis pathways. (A) PDE5-Is induce Ca2+ response 
and the stabilization of F-actin in astrocytes; however, the mechanism behind this effect is not elucidated. Na+/K+-
ATPase interacts with ankyrin B, a cytoskeleton-associated protein, and with the IP3 receptor (IP3R) [coupled to the 
endoplasmic reticulum (ER) membrane], connecting the pump to the Ca2+ responses from internal cell stores and to 
the integrity of the cytoskeleton. It is possible that this mechanism contributes to the dramatic reorganization of actin 
cytoskeleton observed in microglia, macrophages, and astrocytes after stimulation of the cGMP/PKG pathway, leading 
to a more protective phenotype of these inflammatory cells. (B) PDE5-Is have an antiapoptotic effect by enhancing the 
expression of the antiapoptotic Bcl-2 protein and reducing the proapoptotic BAX and caspase-3 proteins. Whether the 
PDE5-Is mechanism involves caspase-mediated apoptosis by extrinsic and/or canonical intrinsic pathway is unclear. 
In the extrinsic pathway, the death receptor-ligand binds to the associated protein with death domain (FADD), which 
activates the initiator pro-caspase-8. Caspase-8 activates caspase-3, inducing apoptosis. The intrinsic apoptotic pathway 
is characterized by mitochondrial changes in response to various stress signals, such as severe genetic damage, 
hypoxia, and oxidative stress, which activate the initiator pro-caspase-9. Proapoptotic mitochondrial proteins, BH3-
only members, activate other proapoptotic proteins, such as BAX, and antagonize antiapoptotic proteins, such as Bcl-2. 
Subsequently, the mitochondrial outer membrane is disrupted, and its permeability increases, resulting in cytochrome-c 
(Cyt-c) leakage into the cytosol. Cyt-c in the cytosol forms a complex with Apaf-1, called the apoptosome, which assists 
in auto-activation of initiator pro-caspase-9. Caspase-9 activates caspase-3, leading to apoptosis.  Inhibition;  
activation;  increased expression/activity/level;  decreased expression/activity.
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showed for the first time that sildenafil has astrocytes as target cells [116], confirming that the 
control of inflammation is not an indirect effect, secondary to neurogenesis, myelin repair, or 
improvement of blood flow.
Although there is no clinical report investigating the use of sildenafil chronically in patients 
with MS, one study has shown the potential of the drug to improve motor impairment. 
Cocchiarella [161] chronically administrated sildenafil (100 mg per day for 7 month) to a 
42-year-old man, who developed a generalized motor deficit with spasticity that made him 
a quadriplegic (but grew normally, including normal intellectual development). The diagno-
sis was inconclusive. Physical therapy evaluation for muscle strength and manual measures 
(scale from 0,  no muscle activity whatsoever, to 5, muscle activity with full range of motion 
and against maximal resistance) by a physical therapist indicated a positive change in muscle 
activity, following sildenafil administration. After stopping the treatment, the patient kept 
all gains. The patient experienced common drug-induced events associated with sildenafil 
treatment, such as erection, headache, and nausea. This study indicates that sildenafil has 
potential to improve other motor deficiencies, such as MS.
Despite the autoimmune/inflammatory nature of MS that has already been described, the 
control of the disease through the use of immunosuppressant and immunomodulators has 
proven to be unsatisfactory. PDE5-Is, being sildenafil the most representative, are widely 
used and well-tolerated drugs, which may be a useful therapeutic intervention to ameliorate 
the neuropathology of MS. Therefore, well-designed clinical trials may demonstrate that oral 
administration of PDE5-Is can be appropriate for individuals with MS and other neuroinflam-
matory/neurodegenerative diseases, providing additional benefits to current treatments.
4.3. Parkinson’s disease and Huntington’s disease
Parkinson’s disease (PD) is a common, slow-progressing neurological disorder that leads to a 
constant loss of motor function. Its clinical features include resting tremor, slow movements 
(bradykinesia), rigidity, impaired balance, difficulty initiating movement (akinesia), and loss 
of postural reflexes [162]. PD is characterized by the death of dopaminergic neurons in the 
substantia nigra, which results in the absence of dopamine release in striatum and therefore 
in motor impairment. The remaining neurons contain intracellular inclusions (Lewy bodies), 
composed of α-synuclein [163] (Figure 1C).
Studies by Uthayathas et al. [164] and by Janis et al. [165] evaluated the use of sildenafil as 
a neuroprotective agent in the murine model of PD induced by chronic 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP). The hypothesis was that the cGMP accumulation would 
attenuate the loss of nigrostriatal dopamine neurons induced by the model. The analysis 
revealed that sildenafil did not prevent neurotoxicity and did not protect against dopamine 
depletion induced by chronic exposure to MPTP. Also, Uthayathas et al. [164] showed that a 
single dose of sildenafil (10 mg/kg i.p.) had no effect on fatigue as seen by swimming time. On 
the other hand, sildenafil did not produce any deleterious effects on nigrostriatal dopamine 
neuron function, nor did it potentiate the neurotoxic effects of MPTP, suggesting that silde-
nafil would not accelerate cell loss when used as a treatment of ED in men diagnosed with 
PD as this drug is used therapeutically to treat sexual dysfunction in PD patients. However, 
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contradictorily, in 2010, a case report by Perkovic et al. [166] described choreoathetotic move-
ments that were most likely induced by sildenafil in a 56-year-old patient with PD. The man 
presented strange, involuntary movements and anxiety after taking sildenafil 100 mg, 50 min 
after the last daily dose of levedopa/carbidopa. These adverse effects were considered to be 
elicited by the administration of sildenafil (drug abuse) in a previously stabilized responder 
to levedopa therapy. This effect may be a predisposition for pharmacokinetic interaction in 
short-time interval between levedopa and sildenafil applied in high dosage.
Despite these negative results using a single dose of sildenafil, therapy with the aim of modu-
lating the immune response and neuroinflammation in PD, targeting microglia, astrocytes, 
and T cells, has recently been proposed [167]. Considerable evidence shows that persistent 
inflammatory response, T-cell infiltration, and glial cell activation [168, 169] are common fea-
tures of human patients and animal models of PD and play a crucial role in the degeneration 
of dopaminergic neurons [170, 171] (Figure 1C). As a result, appropriate treatment appears to 
involve the ability to modulate peripheral and resident immune cells for the purpose of modi-
fying inflammatory response. It is possible that the chronic modulation of neuroinflammation 
by PDE5-Is may be beneficial for PD. Clinical studies demonstrated that while a single dose 
of sildenafil does not cause a clear improvement in cognition in healthy adults [172], chronic 
administration of udenafil has shown to lead to an improvement in cognitive function [130]. 
This has led some to suggest that the therapeutic benefits of PDE5-Is may be better observed 
after chronic inhibition rather than after a single dose [173]. However, studies evaluating the 
anti-inflammatory effects of chronic PDE5-Is in PD models are lacking.
Investigation of the role of cGMP and PDE-Is in Huntington’s disease (HD) is also in the 
beginning. HD is a dominant hereditary neurodegenerative disorder, characterized by pro-
gressive impairment of cognitive and motor functions. This disorder is caused by a mutation 
that encodes an abnormal expansion of CAG-encoded polyglutamine repeats in a protein 
called huntingtin (htt) [174]. While healthy individuals contain 16–20 repeats, more than 36 
are present within the htt gene in HD patients [175]. Toxic protein aggregates are also seen in 
HD patients, whose brains contain accumulations of mutated HTT protein (Figure 1D) [176]. 
The pathological hallmark of HD involves the loss of neurons in the cortex and striatum that 
lead to clinical manifestations including involuntary movements known as chorea, behavioral 
and psychiatric characteristics, and cognitive dysfunction. Mutant huntingtin (mhtt) has been 
reported to impair cAMP and cGMP/CREB signaling, a transcriptional pathway that has been 
hypothesized to play a critical role in HD pathology [177, 178].
It was demonstrated by Saavedra et al. [179] that hippocampal cGMP levels were threefold 
lower in R6/1mice (heterozygous transgenic mice in B6CBA background, expressing exon-1 of 
mhtt with 145 repeats), when they present deficits in object recognition memory and in passive 
avoidance learning. nNOS levels were also downregulated, while there were no changes in 
the levels of PDE5 and PDE9. A single i.p. injection of sildenafil (3 mg/kg), immediately after 
training, increased cGMP levels and improved memory in R6/1 mice. The same study demon-
strated that cGMP levels were also reduced in the human HD hippocampus (six HD patients 
and five control cases). These results showed that the regulation of hippocampal cGMP levels 
may be a suitable treatment for cognitive impairment in HD [179]. Other studies have reported 
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decreased levels of nNOS in the caudate of HD patients [180] and in the striatum and cortex 
of HD mouse models [181, 182]. It has to be investigated whether the mechanism of sildenafil 
protection in HD neural tissue is via NOS, as demonstrated in other neurological disease mod-
els [89, 124, 127, 128].
Puerta et al. [183] demonstrated that the PDE5-Is, sildenafil, and vardenafil (both 1.5 mg/
kg p.o., given twice a day for 5 days) protected against 3-nitropropionic acid (3NP), which 
produces striatal lesions that closely mimic some of the neuropathological features of HD 
(model induced in male Lewis rats). Rats treated with both sildenafil and vardenafil showed 
improved neurologic scores and reduced lesion volume. In addition, striatal pCREB levels 
along with the expression of the downstream target, BDNF, were significantly increased in 
sildenafil-treated rats, and sildenafil reduced death of GABAergic neurons in the brain tissue. 
In addition, the activation of calpain (involved in aggregates formation through calpain/p25/
CDK5 pathway) was reduced, showing that this drug also can avoid huntingtin N-terminal 
fragment aggregates. The mechanism demonstrated by Puerta et al. [183] in the HD model is 
similar to that observed in several studies with AD models.
Also in 2013, Thakur et al. [184] showed that sildenafil was beneficial in the 3NP-HD model 
induced in Wistar rats, improving cognitive and motor functions. Sildenafil (2 and 4 mg/
kg i.p., for 14 days) dose dependently restored body weight and improved memory perfor-
mance and locomotor activity. The PDE5-I attenuated succinate dehydrogenase activity, bal-
ancing the cellular energy deficits induced by 3NP. In addition, as far as we know, this study 
showed for the first time (and was the only one to show) that sildenafil improves oxidative 
and nitrosative stress in HD model, indicating that inflammatory parameters may also be the 
target of this drug in HD.
Despite the lack of studies showing the role of PDE-Is in HD neuroinflammation, several stud-
ies carried out on postmortem HD brain tissue and mouse models of HD have found altered 
expression of immunologically active molecules in the CNS [185–187], and imaging studies 
indicated increased microglial activity in manifest and premanifest HD gene-expansion car-
riers [188, 189]. The mhtt leads to activation of microglia and complement, resulting in subse-
quent production and release of ROS, NO, and cytokines [190]. A study of 20 HD patients, of 
whom 5 were presymptomatic and 15 were symptomatic, as well as 16 age-matched healthy 
controls, showed that there were increased levels of IL-6, MMP-9, vascular endothelial growth 
factor (VEGF), and TGF-β1 in HD patients. These trends were further observed in a murine 
HD model [191]. Politis and coworkers [192] found an increase in the peripheral plasma levels 
of the pro-inflammatory cytokine IL-1β in HD gene carriers compared to normal controls; and 
increased microglial activation in the somatosensory cortex was associated with augmented 
plasma levels of IL-1β, IL-6, IL8, and TNF-α [193]. In addition, the biomarkers of inflamma-
tion were shown to be increased in the plasma of HD gene-expansion carriers, and upregula-
tion was observed up to 16 years prior to expected onset [186, 187, 194], although, in a recent 
study, these findings were not confirmed [195]. On the other hand, Vinther-Jensen et al. [196] 
showed that biomarkers of neurodegeneration increased in manifest HD disease, but did not 
provide evidence of neuroinflammation in early pathogenesis of HD. Therefore, the involve-
ment of neuroinflammation in the HD pathology is not confirmed. However, it is possible that 
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inflammatory events begin years before the onset of the illness. This makes PDE5-Is potential 
tools to prevent HD development through modulating neuroinflammation, while it is only a 
speculation and studies need to be developed.
Therefore, despite the important role of neuroinflammation in PD and HD, there is a lack of 
studies using PDE5-Is to evaluate inflammatory parameters, making this an interesting field 
for exploration.
4.4. Stroke
Although stroke is the third most common cause of death [197] and the leading cause of 
permanent disability in adults worldwide [198], the available therapeutic options remain 
very limited. As vasodilators with good hemodynamic effects, PDE5-Is have been considered 
potential tools to treat hypoxia and stroke. Due to this obvious effect, these drugs were ini-
tially investigated in stroke models considering their mechanisms in cerebral neovasculariza-
tion and blood flow.
Several studies have shown that administration of sildenafil to animal models of stroke has 
beneficial effects [147, 199–201]. It was demonstrated that chronic sildenafil elevated cGMP 
levels in the brain [147], increased angiogenesis in the ischemic border regions, induced cap-
illary-like tube formation, and increased VEGF [199]. Correspondingly, the relative cerebral 
blood flow in the lesion boundary area has also been improved [147, 200]. Sildenafil also 
evoked neurogenesis, increased neuronal and oligodendrocyte progenity, and reduced neu-
rological deficits [147, 201]. However, the drug did not alter the size of the lesion [200, 201]. 
In contrast to these early works, Novitzky et al. [202] reported that sildenafil did not improve 
the conditions of C57BL/6 mice induced model of occlusion of the middle cerebral artery. 
However, in this study, sildenafil was given in a single peritoneal dose (Revatio®, Pfizer; 
0.8 mg/ml), while in other ones, the drug was administered chronically.
To clarify the mechanism of PDE5-I protection in stroke model, a work by Barros-Miñones 
et al. [203] showed that sildenafil reduced the activation of calpain and CDK5 and increased 
the p25/p35 ratio, showing that the protective effects of sildenafil in the ischemia model are, 
at least in part, by similar mechanism observed in other neurological diseases. As described 
above, calpain cleaves p35 in its more stable isoform, p25. Cleavage of p35 to p25 and forma-
tion of the p25/CDK5 complexes are associated with aggregate formation (Figure 2B). As 
expected, sildenafil prevented tau hyperphosphorylation. This study also showed that silde-
nafil increased the expression of the antiapoptotic proteins Bcl-2 and Bcl-xL and reduced cell 
death. The effect of sildenafil on the decrease of apoptosis (through reduction of proapoptotic 
proteins Bax and caspase-3 expression and increasing the antiapoptotic protein Bcl-2) has also 
been demonstrated in physiological aging mouse model [149] (Figure 4B).
Following the same sequence of investigation of other neurological conditions, more recent 
studies have shown that the role of sildenafil in promoting stroke recovery is, at least in part, 
related to the anti-inflammatory mechanism. In 2014, Charriaut-Marlang et al. [148] surgically 
induced ischemia model in P7 Sprague-Dawley rat pups by occlusion in the right common 
carotid artery and tested sildenafil. The animals were treated with a single dose of Viagra® 
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(Pfizer, 10 or 5 mg/kg i.p.). They found that sildenafil increased mean blood flow, reduced 
brain tissue loss, and decreased apoptosis (demonstrated by TUNEL). In addition, sildenafil 
increased the index of myelinated fiber density and improved motor capacity. Associated 
with these beneficial effects, sildenafil had anti-inflammatory effects, reducing astrogliosis 
and GFAP-positive cell density and decreasing microglial density. A very recent study by 
Moretti et al. [204] also demonstrated that sildenafil modulates neuroinflammation in the 
ischemia model induced in C57BL/6 mice P9 pups by permanent middle cerebral artery occlu-
sion. Animals were treated with a single dose of sildenafil (Viagra®, Pfizer, 10 mg/kg i.p., 
given 5 min after artery occlusion), which provided a reduction of the mean lesion 8 days after 
ischemia; also, it reduced the number of GFAP-positive cells, decreased microglial density, 
and modulated the M1 and M2 profiles of microglia/macrophages in the late phase after isch-
emia. The number of activated microglia/macrophages (M2) increased 72 h after artery occlu-
sion, while it decreased 8 days after ischemia in sildenafil-treated animals. However, despite 
the clear anti-inflammatory action of sildenafil in ischemic model, the mechanism behind this 
effect is still unexplained.
A reported clinical study by Silver and coworkers [205] tested the chronic administration of 
sildenafil (25 mg per day, for 90 days) in ten ischemic stroke patients aged 18 to 80 years, with 
a score of 2 to 21 (mild to moderately severe stroke; National Institutes of Health Stroke Scale, 
NIHSS). Sildenafil appeared to be safe in this group of patients, and all of them presented an 
improvement from baseline NIHSS score. However, despite the success in preclinical and 
some clinical studies, PDE5-Is have not been more fully investigated in studies with humans 
and have not moved into clinical practice until now.
5. Conclusion
In conclusion, the relevant role of NO/cGMP signaling in the control of neuroinflammation 
and in the modulation of glial cell activity has lead researchers to investigate the effects of 
PDE5 inhibitors on central neurological diseases. These drugs (sildenafil being the most rep-
resentative and studied among them) have been shown to be safe and effective in the treat-
ment of central neurological disorders, and its mechanisms have been clarified. Modulation 
of neuroinflammation appears to be a relevant mechanism of PDE-Is, mainly in chronic treat-
ments, whereas it has to be more fully investigated. Despite the safety and benefits of this 
class of drugs administrated chronically to patients and the success in preclinical studies, 
there are no Phase I and Phase II clinical trials, which need to be developed to move forward 
the repositioning of PDE5-Is as therapy to treat neurological diseases.
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